Squarepoint
AKCA

Squarepoint’s Akcea Therapeutics Inc AKCA Stock Holding History

Squarepoint’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-68,847
Closed -$985K – 2671
2020
Q1 		$985K Sell
68,847
-74,928
-52% -$1.23M 0.03% 728
2019
Q4 		$2.44M Buy
143,775
+120,321
+513% +$2.24M 0.01% 792
2019
Q3 		$361K Sell
23,454
-45,226
-66% -$963K ﹤0.01% 1795
2019
Q2 		$1.61M Buy
68,680
+48,841
+246% +$1.21M 0.02% 970
2019
Q1 		$562K Buy
19,839
+6,337
+47% +$185K 0.01% 1426
2018
Q4 		$407K Buy
13,502
+1,202
+10% +$33.7K ﹤0.01% 1365
2018
Q3 		$431K Buy
+12,300
New +$372K 0.01% 1372

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Squarepoint's AKCA Position: Q2 2020 in Review

Squarepoint sold out of Akcea Therapeutics Inc (AKCA) in Q2 2020, closing a stake of 68,847 shares — an estimated $985K sold.

Squarepoint first reported a position in AKCA in Q3 2018 and held it in 7 quarters. The position peaked at $2.44M in Q4 2019. 84 funds tracked by Wall St. Rank hold AKCA as of Q2 2020.

  • Squarepoint reported no remaining Akcea Therapeutics Inc position as of Q2 2020 after selling out during the quarter.
  • Squarepoint sold 68,847 Akcea Therapeutics Inc shares in Q2 2020, an estimated $985K.
  • Squarepoint first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 7 quarters.
  • Squarepoint's Akcea Therapeutics Inc position peaked at $2.44M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2020.

Based on Squarepoint's 13F filing for Q2 2020, filed 14 Aug 2020.